Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Measuring—and delivering—what consumers really want by Eric Almquist, John Senior and Nicolas Bloch When customers evaluate a product or service, they weigh its perceived value against the asking ...

Micah Castelo is a web editor for EdTech: Focus on K-12. Her experience includes education and community news coverage for the Syracuse Post-Standard and international news reporting for the Pulitzer ...